Your compensation depends on various factors but can go as high as $700K
Novo Nordisk is coming under fire for the unintended side effects of semaglutide, the active ingredient in the brand names of Ozempic, Wegovy, and Rybelsus. Ozempic has been FDA-approved since 2017 and is prescribed for type II diabetics to help them lower their blood sugar. It is also heavily marketed as a weight loss aid with off-label use.
Despite the growing popularity of Ozempic, Novo Nordisk failed to disclose the severe potential side effects of taking the drug: gastroparesis, or stomach paralysis, and serious intestinal obstructions. Intestinal blockages were only added as a warning to the label in late 2023, while gastroparesis is still not included as a possible side effect of the drug.
If you are experiencing any serious side effects such as gastroparesis or bowel obstructions that resulted in your hospitalization due to the use of Ozempic, contact your doctor and get a proper diagnosis as soon as possible. This will be the starting point of your claim against Novo Nordisk.
The diagnosis should detail the severity of your condition. It is important to note the exact date when you started taking the drug as well. These factors will affect the value of the compensation you may receive.
Our firm will provide you with the legal assistance you need
Over 500 people across 45 states have come forward with their claims against Novo Nordisk. If you are interested in possibly receiving financial compensation from the manufacturer, you will need an experienced law firm to get you the maximum amount possible. Our law firm knows how to deal with negligent entities—we've been in the field of personal injury for over three decades.
Because we understand that this is a stressful time for you and your family, we want to make this process as straightforward as possible for you. Simply reach out to us with your medical records and we will quickly determine whether you are eligible to file a case. From there, we will handle the legal process on your behalf.